Roselle, M.D., DVA Program Director for Infectious Diseases, 3200 Vine St., Cincinnati, OH 45220. Tel.: (513) 475-6398.

Gonococcal Isolate Surveillance Project (GISP) http://www.cdc.gov/ncidod/dastlr/gcdir/Resist/gisp.html

GISP, established in 1986, is a collaborative project to monitor antimicrobial resistance in Neisseria gonorrhoeae in the United States and to establish a rational basis for the selection of gonococcal therapies. Participants also pheno-typically characterize antimicrobial-resistant isolates as a means to describe the diversity of antimicrobial resistance to N. gonorrhoeae. Participants are the CDC (Division of STD Prevention, National Center for HIV, STD, and TB Prevention, and the Division of AIDS, STD, and TB Laboratory Research of the National Center for Infectious Diseases), five regional laboratories, and selected STD clinics). Data and isolates are collected from STD clinics in 26 cities. Data from this project have been used to revise the CDC's STD Treatment recommendations in 1989, 1993, and 1997. Contact: Joan Knapp, Ph.D., Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, CDC, Atlanta, GA 30333. Tel.: (404) 639-2840.

Herpes Simplex Virus Surveillance

Herpes simplex virus isolates are tested for acyclovir resistance from patients in 22 STD and HIV clinics in 12 U.S. cities. In December 1997, funding from a pharmaceutical sponsor of this project expired. Currently, new sources of funding are being explored. Contact: Michelle Teyes, Ph.D., Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, Atlanta, GA 30333. Tel.: (404) 639-3921.

Human Immunodeficiency Virus Surveillance

During 1998, CDC will begin conducting antiretroviral drug susceptibility testing on HIV strains obtained from groups of patients believed to have recently acquired HIV infection and/or for whom recommendations for drug prophylaxis to prevent transmission have been made. These include adult seroconverters, adult patients beginning antiretroviral therapy, women and infants in perinatal transmission studies, and source patients involved in health care worker needle-stick exposures. Funds have been awarded and equipment purchased. The objective is to study specimens from approximately 1,000 patients per year. Contact: Walid Heneine, Ph.D., Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, CDC, Atlanta, GA 30333. Tel.: (404) 639-0218.

INSPEAR

In collaboration with several European investigators, the CDC has initiated an International Surveillance Program for Emerging Antimicrobial Resistance (INSPEAR) specifically focusing on nosocomial infections. This project in-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement